Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6762868 | 1.00 | OPRK1 (0.44) | OPRK1KCNH2NAAAGRIN1GRIN2B | |
| SCHEMBL6154249 | 1.00 | OPRK1 (0.44) | OPRK1KCNH2NAAAGRIN1GRIN2B | |
| SCHEMBL6761241 | 0.88 | NAAA (0.45) | OPRK1KCNH2NAAAGRIN1GRIN2B | |
| SCHEMBL6761237 | 0.88 | NAAA (0.45) | OPRK1KCNH2NAAAGRIN1GRIN2B | |
| SCHEMBL6761414 | 0.86 | OPRK1 (0.44) | OPRK1KCNH2NAAAGRIN1GRIN2B | |
| SCHEMBL6761413 | 0.86 | OPRK1 (0.44) | OPRK1KCNH2NAAAGRIN1GRIN2B | |
| SCHEMBL6760350 | 0.83 | NAAA (0.47) | OPRK1KCNH2NAAAGRIN1GRIN2B | |
| SCHEMBL6760352 | 0.83 | NAAA (0.47) | OPRK1KCNH2NAAAGRIN1GRIN2B | |
| SCHEMBL20958268 | 0.83 | NAAA (0.47) | OPRK1KCNH2NAAAGRIN1GRIN2B | |
| SCHEMBL20958266 | 0.83 | NAAA (0.47) | OPRK1KCNH2NAAAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1525201-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR1 CHEMOKINE RECEPTOR | Pfizer Products Inc. (US) | 2005-04-27 | — | — | EP | disclosed |
| US-20040063688-A1 | Novel piperidine derivatives | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2004009588-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR1 CHEMOKINE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063688-A1 | Novel piperidine derivatives | CCR1, CCR3, CCR2 | OPRK1 57/4885KCNH2 1989/4885NAAA 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.